Clinical Trial Update: Extension Study of Etelcalcetide in the Treatment of Secondary Hyperparathyroidism (SHPT) in Patients With Chronic Kidney Disease (CKD) on Hemodialysis [Phase 3]

View source ↗

Summary

A Phase 3 extension study of etelcalcetide in secondary hyperparathyroidism due to chronic kidney disease on hemodialysis has completed with results posted in 2…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hyperparathyroidism Secondary

Drugs mentioned

• Etelcalcetide (etelcalcetide)

Snippet

Sponsor: Amgen | Conditions: Hyperparathyroidism, Secondary | Phase 3 | Status: COMPLETED | Results posted: 2017-03-27